Latest dyslipidemia Stories
Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent THOUSAND OAKS, Calif., Nov.
THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
DALLAS, October 21, 2014 /PRNewswire/ -- RnRMarketResearch.com adds EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023 market research of 94 pages to the Therapeutics
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Aug.
Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug.
Agents That Reduce the Incidence of Cardiovascular Adverse Events Remain a Key Unmet Need for Both Physicians and Payers, According to Findings from Decision Resources Group BURLINGTON, Mass.,
Data From Two Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented in Late-Breaking Clinical Trials Session at ACC.14 - Data Add to the Three Pivotal Studies Presented Yesterday THOUSAND
Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ --
LONDON, March 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
- To give a box on the ear to.